DE602005020313D1 - Bisaryl-sulfonamide - Google Patents

Bisaryl-sulfonamide

Info

Publication number
DE602005020313D1
DE602005020313D1 DE602005020313T DE602005020313T DE602005020313D1 DE 602005020313 D1 DE602005020313 D1 DE 602005020313D1 DE 602005020313 T DE602005020313 T DE 602005020313T DE 602005020313 T DE602005020313 T DE 602005020313T DE 602005020313 D1 DE602005020313 D1 DE 602005020313D1
Authority
DE
Germany
Prior art keywords
bis
pparδ
pparγ
prevention
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005020313T
Other languages
English (en)
Inventor
Philippe Bergeron
Christopher N Farthing
Stuart D Jones
John W Liebeschuetz
Sarah E Lively
Lawrence R Mcgee
Sharon Mckendry
David Sheppard
Stephen C Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DE602005020313D1 publication Critical patent/DE602005020313D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/58—Two sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602005020313T 2004-08-12 2005-08-11 Bisaryl-sulfonamide Active DE602005020313D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60157804P 2004-08-12 2004-08-12
PCT/US2005/028673 WO2006020830A2 (en) 2004-08-12 2005-08-11 Bisaryl-sulfonamides

Publications (1)

Publication Number Publication Date
DE602005020313D1 true DE602005020313D1 (de) 2010-05-12

Family

ID=35908167

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005020313T Active DE602005020313D1 (de) 2004-08-12 2005-08-11 Bisaryl-sulfonamide

Country Status (8)

Country Link
US (2) US7544702B2 (de)
EP (1) EP1786782B1 (de)
AT (1) ATE462697T1 (de)
AU (1) AU2005272786B2 (de)
CA (1) CA2576993C (de)
DE (1) DE602005020313D1 (de)
ES (1) ES2343640T3 (de)
WO (1) WO2006020830A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
DE602005020313D1 (de) 2004-08-12 2010-05-12 Amgen Inc Bisaryl-sulfonamide
JP5128603B2 (ja) * 2006-10-04 2013-01-23 エフ．ホフマン−ラ ロシュ アーゲー フェノキシジアミノピリミジン誘導体の合成方法
CN101863830B (zh) * 2010-06-22 2012-07-25 浙江科源化工有限公司 2-氨基-5-溴异烟酸的合成方法
CN102321016B (zh) * 2011-07-29 2013-04-10 山东轻工业学院 5-溴-2-羟基异烟酸甲酯的合成方法
RU2014121983A (ru) * 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US8952169B2 (en) 2012-05-22 2015-02-10 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
EP2870138B1 (de) 2012-07-06 2018-08-22 Genentech, Inc. N-substituierte benzamide und verfahren zur verwendung davon
CA2898679A1 (en) 2013-03-14 2014-09-25 Xenon Pharmaceuticals Inc. Substituted triazolopyridines and methods of use thereof
EP2970156B1 (de) 2013-03-15 2018-07-25 Genentech, Inc. Substituierte benzoxazole und verfahren zur verwendung davon
CN105793238B (zh) 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
US10005724B2 (en) 2014-07-07 2018-06-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
MX2017014715A (es) 2015-05-22 2018-03-16 Genentech Inc Benzamidas sustituidas y metodos para utilizarlas.
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3356360A1 (de) 2015-09-28 2018-08-08 Genentech, Inc. Therapeutische verbindungen und verfahren zur verwendung davon
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
CN109071426A (zh) 2016-03-30 2018-12-21 基因泰克公司 取代的苯甲酰胺及其使用方法
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
RU2019114964A (ru) 2016-10-17 2020-11-17 Дженентек, Инк. Терапевтические средства и способы их применения
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
US11028075B2 (en) 2018-02-26 2021-06-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3774801A1 (de) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Hydro-pyrido-verbindungen mit kondensierten ringen als natriumkanalinhibitoren
CN113773247A (zh) * 2021-07-23 2021-12-10 无锡海伦生物科技有限公司 一种2-氨基-5-碘吡啶的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB824598A (en) 1957-02-14 1959-12-02 Rhone Poulenc Sa Improvements in or relating to new phenthiazine derivatives and processes for their preparation
BE577515A (fr) 1959-04-09 1959-10-09 Henri Morren Dérives de pyridazine.
US4096264A (en) * 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
EP0173361B1 (de) 1984-08-11 1988-10-19 Agfa-Gevaert N.V. Organische Verbindungen zur Verwendung in einem Farbdiffusionsübertragungsverfahren und solche Verbindungen enthaltende photographische Elemente
CS254541B1 (cs) * 1986-05-04 1988-01-15 Alois Novacek Sulfonamidy na bázi trimethoprimu
US5112971A (en) 1988-08-10 1992-05-12 Sumitomo Chemical Company, Limited Anthraquinone dye compounds having fibers reactive group
FR2650275A1 (fr) * 1989-07-28 1991-02-01 Shimi Ibrahim Nouveaux derives sulfamides, leur procede d'obtention et leur application comme medicament
US5403816A (en) * 1990-10-25 1995-04-04 Kumiai Chemical Industry Co., Ltd. Picolinic acid derivative and herbicidal composition
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
JPH10114744A (ja) * 1996-08-22 1998-05-06 Takeda Chem Ind Ltd アミノグアニジンヒドラゾン誘導体、その製法及び剤
US6646008B1 (en) 1996-12-31 2003-11-11 The Salk Institute For Biological Studies Treatment of disease states which result from neoplastic cell proliferation using PPAR-γ activators and compositions useful therefor
EP1053227B1 (de) * 1998-01-29 2008-11-05 Amgen Inc. Ppar-gamma modulatoren
WO1999059587A1 (en) 1998-05-20 1999-11-25 Eli Lilly And Company Anti-viral compounds
US6248781B1 (en) 1998-10-21 2001-06-19 Novo Nordisk A/S Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
AU2871900A (en) * 1999-02-04 2000-08-25 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
NZ516455A (en) 1999-06-30 2004-03-26 Tularik Inc Compounds for the modulation of PPARgamma activity
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU7115300A (en) 1999-09-08 2001-04-10 Glaxo Group Limited Oxazole ppar antagonists
JP2001083656A (ja) 1999-09-13 2001-03-30 Konica Corp プリントアウトを改良した熱現像感光材料
JP2001089412A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
AU5759499A (en) 1999-09-24 2001-04-24 Kyorin Pharmaceutical Co. Ltd. Pparalpha and ppargamma inhibitors
KR100771286B1 (ko) 2000-06-28 2007-10-29 암젠 인크 퀴놀리닐 및 벤조티아졸릴 ｐｐａｒ-감마 조절물질
GB0024361D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
US6756399B2 (en) 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
JP4269052B2 (ja) 2001-09-14 2009-05-27 アムジエン・インコーポレーテツド 連結ビアリール化合物
TWI328007B (en) 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
PA8594401A1 (es) 2003-02-21 2004-09-16 Pfizer Acidos carboxilicos de heteroarilo condensado como agonista del ppar
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
DE602005020313D1 (de) 2004-08-12 2010-05-12 Amgen Inc Bisaryl-sulfonamide

Also Published As

Publication number Publication date
ES2343640T3 (es) 2010-08-05
WO2006020830A2 (en) 2006-02-23
US7893077B2 (en) 2011-02-22
US7544702B2 (en) 2009-06-09
WO2006020830A3 (en) 2007-04-12
EP1786782B1 (de) 2010-03-31
US20060084802A1 (en) 2006-04-20
US20090221584A1 (en) 2009-09-03
AU2005272786A1 (en) 2006-02-23
CA2576993A1 (en) 2006-02-23
AU2005272786B2 (en) 2011-12-22
ATE462697T1 (de) 2010-04-15
EP1786782A2 (de) 2007-05-23
CA2576993C (en) 2013-09-24

Similar Documents

Publication Publication Date Title
DE602005020313D1 (de) Bisaryl-sulfonamide
MX2007011859A (es) Compuestos mejorados farmacocineticamente.
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
MX2009005053A (es) Emulsiones bituminosas.
EP2174360A4 (de) Wandler mit elektroaktivem polymer für anwendungen der sensorischen rückmeldung
TW200736253A (en) Pyridopyrazine derivatives and their use
NO20052769L (no) Enkeldomene antistoffer rettet mot tumor nekrose faktor-alfa og anvendelser derav
TW200705255A (en) Ring management
ATE486165T1 (de) Oberflächenbehandlungszusammensetzungen mit saccharid-siloxan-polymeren
EP2248430A3 (de) Nahrungsmittel mit probiotischem und isoliertem Beta-Glucan und Verwendungsverfahren dafür
MY147669A (en) Anti-alpha2 integrin antibodies and their uses
MX2009003575A (es) Metodo para el tratamiento hidrofobo de particulas de pigmento y composiciones de cuidado personal que comprenden estas particulas de pigmento.
TW200606483A (en) Methods for rotationally stabilizing contact lenses
TW200643153A (en) Liquid-crystalline medium
CY1111864T1 (el) Παραγωγα του ενζυμου που διεγειρει nf-καππαβ, παρασκευη αυτων και χρηση αυτων
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
TN2010000155A1 (en) Organic compounds
MX2009002684A (es) Derivados de acido nicotinico como moduladores de receptores de glutamato metabotropico.
UA102115C2 (ru) Дизамещенные фталазиновые антагонисты сигнального пути hedgehog
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
EP3864217A4 (de) Veredlerplatte mit verschleissvorsprüngen zwischen den barren
MX2007013262A (es) Metodo de construccion y tratamiento de pozos.
WO2009046229A3 (en) Animal waste removal device
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
MX2010002950A (es) Metodos y composiciones para deteccion de ehrlichia chaffeensis (vlpt).

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1786782

Country of ref document: EP